BRCA1-methylated triple negative breast cancers previously exposed to neoadjuvant chemotherapy form RAD51 foci and respond poorly to olaparib

BACKGROUND: About 15% of Triple-Negative-Breast-Cancer (TNBC) present silencing of the BRCA1 promoter methylation and are assumed to be Homologous Recombination Deficient (HRD). BRCA1-methylated (BRCA1-Me) TNBC could, thus, be eligible to treatment based on PARP-inhibitors or Platinum salts. However...

Descripción completa

Detalles Bibliográficos
Autores principales: Velazquez, Carolina, Orhan, Esin, Tabet, Imene, Fenou, Lise, Orsetti, Béatrice, Adélaïde, José, Guille, Arnaud, Thézénas, Simon, Crapez, Evelyne, Colombo, Pierre-Emmanuel, Chaffanet, Max, Birnbaum, Daniel, Sardet, Claude, Jacot, William, Theillet, Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064050/
https://www.ncbi.nlm.nih.gov/pubmed/37007122
http://dx.doi.org/10.3389/fonc.2023.1125021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064050/
https://www.ncbi.nlm.nih.gov/pubmed/37007122
http://dx.doi.org/10.3389/fonc.2023.1125021

Ejemplares similares